Cancer – Multikine®

Multikine®, CEL-SCI’s flagship cancer product, is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Multikine® is a different kind of weapon in the fight against cancer; one that harnesses our body’s natural ability to fight tumors.

Multikine® is also the first of a new class of cancer immunotherapy drugs. It is the first combination immunotherapy, possessing both active and passive properties.

Multikine® is the only immunotherapy that is able to directly affect both the tumor cells themselves and activate a robust anti-tumor immune response. Read more about Multikine

CEL-SCI’s business strategy is to create genuinely new, valuable and unique therapies that meet unmet medical needs, as opposed to minor innovations to existing therapies or ‘me-too’ products. Multikine® is such an innovation.

In order to truly understand how Multikine® is different from other immunotherapy products, we invite you to read a brief summary of the field of cancer immunotherapy, as well as the limitations to these current therapies.